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The Plasmodium proteasome has been suggested to
be a potential antimalarial drug target; however,
toxicity of inhibitors has prevented validation of this
enzyme in vivo. We report a screen of a library of
670 analogs of the recent US Food and Drug
Administration-approved inhibitor, carfilzomib, to
identify compounds that selectively kill parasites.
We identified one compound, PR3, that has signifi-
cant parasite killing activity in vitro but dramatically
reduced toxicity in host cells. We found that this
parasite-specific toxicity is not due to selective
targeting of the Plasmodium proteasome over the
host proteasome, but instead is due to a lack of
activity against one of the human proteasome sub-
units. Subsequently, we used PR3 to significantly
reduce parasite load in Plasmodium berghei infected
micewithout host toxicity, thus validating the protea-
some as a viable antimalarial drug target.
INTRODUCTION
Malaria is a devastating disease that affects approximately
250 million people per year, resulting in more than 800,000
deaths annually (World Health Organization, 2011). The majority
of human malaria is caused by the pathogen Plasmodium falci-
parum. Parasite resistance to inexpensive antimalarial drugs,
such as chloroquine and sulfadoxine-pyrimethamine, is wide-
spread, and resistance to newer artimisinin-based combination
therapies (ACTs), the current gold standard in malaria treatment,
is emerging (Dondorp et al., 2009). Despite a clear need for new
antimalarial therapies, the high cost of new drug development
and relatively low profit associated with drugs that will be used
predominantly in the developing world present many challenges.
One approach to lowering the cost of antimalarial drug develop-
ment is to evaluate compounds that are in clinical developmentChemistry & Biology 19, 1535–154and associated synthetic analog libraries for potential antima-
larial activity.
The proteasome is a large multi-subunit protein complex that
consists of a barrel-shaped proteolytic core (20S) and regulatory
factors that flank each end of the barrel to regulate entry of
proteins targeted for degradation (Bedford et al., 2010). The
microenvironment within the 20S proteasome harbors the sites
of protein degradation with its barrel-shaped structure made
up of two stacked rings of seven b subunits sandwiched
between two rings of a subunits. In the catalytic core of the yeast
and mammalian proteasome, only b1, b2, and b5 subunits have
catalytic activity. b1 has caspase-like activity, preferring to
cleave after acidic residues; b2 has trypsin-like activity, prefer-
ring to cleave after basic residues; and b5 has chymotrypsin-
like activity, preferring to cleave after non-polar residues
(Verdoes et al., 2009). Studies using site-directed mutagenesis
of the catalytic residues in each of the active sites showed that
inactivation of the b5 subunit caused the most drastic pheno-
typic changes in yeast (Heinemeyer et al., 1997). The protea-
some regulates numerous cellular functions, including normal
turnover of proteins, degradation of misfolded proteins, and
regulation of biologic pathways by selective degradation of
regulatory proteins and transcription factors (Voges et al.,
1999; Voorhees et al., 2003). In rapidly proliferating tumor cells,
exposure to proteasome inhibitors leads to cell cycle arrest
and subsequent apoptosis (Orlowski and Kuhn, 2008). This
increased sensitivity to proteasome inhibition over quiescent
cells led to the development of proteasome inhibitors now
used for treatment of multiple myeloma.
Proteasome inhibitors have also been found to effectively kill
various parasitic organisms such as Mycobacterium tubercu-
losis (Lin et al., 2009), Trypanosome brucei (Mutomba et al.,
1997; Steverding et al., 2011), and Plasmodium spp. Over the
past decade, several groups have reported that multiple classes
of proteasome inhibitors block P. falciparum asexual replication
in red blood cells (Tschan et al., 2011; Li et al., 2012). Some of
these compounds have been shown to be effective not only
toward asexual stages (Lindenthal et al., 2005; Kreidenweiss
et al., 2008) of the P. falciparum life cycle, but also during the5, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1535
Figure 1. Antiparasitic Activity and Therapeutic Window of
Carfilzomib In Vitro
(A) Structure of carfilzomib. The epoxyketone reactive functional group is
shown in red.
(B) Dose response of carfilzomib on P. falciparum culture and HFF. Synchro-
nous P. falciparum trophozoites or non-confluent HFF cells were treated for
1 hr followed by washout of the inhibitor and incubation for 60 hr (trophozoite)
or 72 hr (HFF). Each concentration was tested at least three times; error bars
represent standard error of the mean (SEM) for each drug concentration from
triplicates. EC50 value is shown as mean ± standard deviation (SD). The
dose-response curve for 60 hr treatment is shown in Figure S2.
(C) Proteasome activity in intact trophozoites treated with carfilzomib. Pro-
teasome activity was assessed by monitoring inhibition of the putative b5
subunit (assignment of labeled subunit is shown in Figure S1). Synchronous
mid-trophozoite stage parasites were treated with the indicated concentra-
tions of carfilzomib for 1 hr, followed by inhibitor washout and preparation of
parasite lysates. Residual proteasome activity of parasite lysate under each
drug concentration was determined by labeling with 2 mM MV151. The IC50
curve was obtained from three independent experiments; error bars represent
SEM for each drug concentration from triplicates. A representative probe
competition gel is shown in Figure S5. IC50 value is shown as mean ± SD.
See also Figure S2.
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The Proteasome as a Drug Target in Plasmodiumsexual (Czesny et al., 2009; Aminake et al., 2011) and insect-
vector stages (Gantt et al., 1998). This makes the Plasmodium
proteasome a highly attractive drug target because it has impor-
tant functions in all stages of the parasite life cycle. However,
despite promising results in vitro, translation into animal studies
has been limited due to toxicity resulting from cross-reactivity
with the host proteasome (Gantt et al., 1998). Furthermore,
none of the current studies have been able to directly link effects
of compounds in parasite replication to proteasome inhibition
and a clear understanding of the key parameters required for effi-
cient parasite killing by proteasome inhibitors in vivo is lacking.
Carfilzomib (PR-171; Kyprolis) is a proteasome inhibitor devel-
oped by Onyx Pharmaceuticals (South San Francisco) that has
just recently been approved by the US Food and Drug Adminis-
tration for the treatment of multiple myeloma. Carfilzomib is
a potent, highly selective, and irreversible inhibitor of the protea-
some (Demo et al., 2007; Kuhn et al., 2007). Here, we describe
our efforts to screen a library of 670 analogs of carfilzomib to
identify inhibitors that selectively target P. falciparum relative to
the human proteasome. We identified one molecule, PR3, that
inhibits P. falciparum replication, proteasome activity, and
gametocyte survival and has overall low toxicity to host cells.
Interestingly, we found that PR3 does not selectively target the
Plasmodium proteasome but rather derives its lack of toxicity
in the host from its inability to target the human b2 subunit. As
a result, PR3 is able to significantly decrease parasitemia in
mice with no host toxicity during treatment. The findings from
this study validate the Plasmodium proteasome as a target for
antimalaria drugs and provide important insight into the key
parameters required of proteasome inhibitors for effective
clearance of parasites in vivo.
RESULTS
Antiparasitic Effects of Carfilzomib In Vitro and In Vivo
Carfilzomib (Figure 1A) is a synthetic proteasome inhibitor that
is an analog of the natural product epoxomicin. While there
have not been any reports on the effects of carfilzomib on
P. falciparum, the related compound epoxomicin has been
shown to block replication of chloroquine-susceptible, chloro-
quine-resistant, and clinical isolates of P. falciparum in vitro
(Kreidenweiss et al., 2008; Czesny et al., 2009). We chose carfil-
zomib as a starting point for our study because it was recently
approved for use for the treatment of multiple myeloma and
a significant amount of preclinical toxicity, pharmacokinetic
(PK) and adsorption, distribution, metabolism, and excretion
(ADME) data are available (Yang et al., 2011). To evaluate the
potency of carfilzomib against P. falciparum, we monitored its
effects on parasite replication in vitro using flow cytometry as
previously described (Arastu-Kapur et al., 2008). Because carfil-
zomib has a short half-life in vivo, we chose to perform a 1 hr
treatment to more closely reflect in vivo conditions. We treated
P. falciparum cultures in the trophozoite stage with carfilzomib
or vehicle for 1 hr at 37C, washed extensively with fresh media,
and then allowed the parasite to replicate. Like epoxomicin, car-
filzomib potently blocked parasite replication with an effective
concentration (EC50) of 28.8 ± 0.8 nM even with a short exposure
time of 1 hr (Figure 1B). We noted that with prolonged treatment
(60 hr), there is a 5-fold increase in potency of carfilzomib1536 Chemistry & Biology 19, 1535–1545, December 21, 2012 ª2012 Elsevier Ltd All rights reserved
Figure 2. Carfilzomib Fails to Effectively
Block Parasite Growth In Vivo
Female Balb/c mice infected with 1 3 106 P. ber-
ghei parasites via tail vein injection were dosed
intravenously with vehicle (n = 4), 0.5 mg/kg car-
filzomib (n = 3), or 1 mg/kg carfilzomib (n = 3) on 3
consecutive days (as indicated by line below the x
axis). Parasitemia was quantified by microscopy
counting of Giemsa-stained thin blood smears.
The asterisk represents p < 0.05. Error bars
represent SEM.
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toxicity of carfilzomib using a nontransformed human foreskin
fibroblast (HFF) cell line. To match the replicative nature of the
parasite, we used nonconfluent HFF cells grown at low density.
As expected, we found that 1 hr treatment with carfilzomib is also
able to effectively kill host cells with an EC50 of 492 ± 23 nM (Fig-
ure 1B). These data suggest that there is only a small therapeutic
window for use of this drug without causing potentially signifi-
cant side effects.
We next wanted to confirm that growth inhibition in the replica-
tion assay correlates with inhibition of Plasmodium proteasome
activity. Therefore, we exposed intact trophozoites for 1 hr with
a range of concentrations of carfilzomib and monitored protea-
some activity in the treated parasites using a proteasome selec-
tive activity-based probe (MV151; Figure S1; (Verdoes et al.,
2006)). Using MV151, we are able to monitor the activity of two
(putative b2 and b5; Figure S1) of three predicted active sites
in Plasmodium proteasome. We found that the IC50 for the puta-
tive parasite b5 subunit after 1 hr treatment of trophozoites with
carfilzomib (25 ± 3 nM) closely matches the EC50 of the
compound for parasite growth (Figure 1C). These data, coupled
with the high degree of selectivity of the epoxyketone functional
group for the proteasome, suggest that carfilzomib blocks para-
site growth as a direct result of specific inhibition of the parasite
proteasome.
Although wewere aware that carfilzomib could only be used at
low doses in vivo, we wanted to determine if the drug could
reduce parasite burden at its maximum tolerated dose. We
used the Plasmodium berghei mouse model of malaria since
P. falciparum can only infect humans and New World monkeysChemistry & Biology 19, 1535–1545, December 21, 2012 ª(Aotus and Saimiri sp.). Mice were in-
fected with P. berghei via intravenous
(IV) injection of parasites, treated for 3
consecutive days with daily IV doses of
carfilzomib, and monitored for parasite
burden (Figure 2). We tested a range of
doses from 0.5 to 4 mg/kg, and found
that signs of compound toxicity (scruffy
coat, significant weight loss during treat-
ment) developed in the mice at 1 mg/kg
of carfilzomib and therefore we had to
stop treatment at the higher doses. We
noted that the maximum tolerable dose
for the P. berghei-infected mice was
lower than the previously reported 2 mg/
kg for 5 consecutive days of treatment(Demo et al., 2007), and we think this is likely because these
mice are more susceptible to the toxic effects of the inhibitor
as a result of parasite burden. Our results for 3 days of treatment
at the tolerated dose of carfilzomib showed only a very minor
effect on parasite burden at day 3, and parasitemia returned to
control levels by day 4 (Figure 2).
To investigate why carfilzomib only had a moderate effect on
lowering parasitemia in vivo, we treated a culture of P. falciparum
trophozoites at high parasitemia with carfilzomib for 1 hr,
washed out the inhibitor extensively, and then monitored para-
site proteasome activity (Figure 3A). We found that once the
inhibitor was removed, proteasome activity recovered within
24 hr or less depending on the dose. Because carfilzomib is
a covalent inhibitor and treatment permanently inhibits pro-
teasomes, this recovery of activity is most likely due to new
synthesis of the enzyme complex (Meiners et al., 2003). We
found that the amount of proteasome recovery is also dependent
on the inhibitor dose. A dose that far exceeds the IC50 (1 hr) for
carfilzomib (20 mM) was required to achieve complete inhibition
of proteasome activity with no further recovery. Surprisingly,
even at a relatively high dose of carfilzomib treatment (1 mM),
there was substantial recovery of proteasome activity after
47 hr of compound washout. These data, combined with the
data shown in Figure 1, suggest that even partial inhibition of
the proteasome is sufficient to significantly block Plasmodium
growth. In agreement with previous reports on proteasome
inhibitor treatment of P. falciparum (Gantt et al., 1998; Lindenthal
et al., 2005), we found that low doses of the inhibitor slowed
parasite growth but resulted in parasite death only at high
concentrations of the compound (Figure 3B).2012 Elsevier Ltd All rights reserved 1537
Figure 3. P. falciparum Recovers Protea-
some Activity after a Short Period of Inhibi-
tion and Prolonged Proteasome Inhibition
Prevents Recovery
(A) Recovery of P. falciparum proteasome activity
after 1 hr treatment with carfilzomib. A synchro-
nous culture of trophozoites was treated at the
indicated concentrations of carfilzomib for 1 hr
followed by extensive washout of the inhibitor.
Parasites were kept in fresh media for a further
47 hr, and proteasome activity in lysates obtained
at different time points was determined by labeling
with MV151 (see Figure S1). To adjust for variation
of proteasome content due to parasite growth,
proteasome activity was normalized to DMSO
treated parasites obtained at each respective time
point. Proteasome activity at each time point was
assessed by intensity of probe labeling. Quantifi-
cation of the putative b5 subunit labeling is shown
in the graph below the gel image.
(B) Giemsa-stained thin blood smears of
P. falciparum culture treated with carfilzomib for
1 hr followed by 47 hr washout.
(C) Synchronous trophozoites were treated with
100 nM or 1 mM carfilzomib for the indicated times
followed by inhibitor wash out. Parasites were
placed in fresh media, and proteasome activities
of all samples were determined by MV151 labeling
at 10 hr after inhibitor washout. Quantification of
the putative b5 subunit labeling is shown in the
graph below the gel image.
See also Figure S1.
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if prolonged exposure of parasites to the inhibitor leads to
sustained proteasome inhibition and therefore parasite death,
even at a low concentration of the drug. Therefore, we treated
P. falciparum trophozoites with two concentrations of carfilzo-
mib for different time periods followed by washout and moni-
toring of proteasome recovery at the end of the washout period
(Figure 3C). These results suggest that increasing treatment
time indeed reduced the ability of the parasite to recover protea-
some activity. However, at the 100 nM dose (close to EC50 of
carfilzomib against parasites in culture), at least 6 hr of inhibitor
exposure was necessary to prevent recovery of proteasome
activity. This result, combined with our observation of rapid pro-
teasome recovery, likely explains why carfilzomib, which has
a short half-life in the bloodstream (Yang et al., 2011), is unable
to clear parasites without host toxicity even when used at a dose
far above its EC50 for parasite killing in vitro. These data also
indicate that any inhibitors designed in the future would likely
need to have long half-life in blood to efficiently effect parasite
clearance.1538 Chemistry & Biology 19, 1535–1545, December 21, 2012 ª2012 Elsevier Ltd All rights reScreen to Identify P. falciparum
Proteasome Selective Inhibitors
We reasoned that since carfilzomib has
high overall toxicity but is an effective
inhibitor of parasite growth, it should be
possible to find analogs that retain the
killing effects against the parasite but
that are overall poor inhibitors of thehuman enzyme. We therefore screened a library of 670 analogs
of carfilzomib (generated at Proteolix, acquired by Onyx) for inhi-
bition of ring-stage P. falciparum replication in culture after a
72-hr treatment (Figure 4A). From this initial screen, we identified
a total of 592 compounds that inhibited parasite replication by
greater than 50% at 500 nM. We then cross-referenced these
‘hits’ with their measured potency against the human protea-
some. This resulted in an initial 52 preliminary hits that had less
than 50% inhibition of human proteasome at 500 nM concentra-
tion. We then determined the EC50 values for these hits and
selected the top eight compounds with EC50 values for parasite
killing at or below 50 nM for 72 hr inhibitor treatment. These eight
compounds were then tested for their ability to inhibit partially
purified P. falciparum proteasomes that were isolated from para-
site extracts using a number of standard protein purification
steps (refer to Figure S1 and Supplemental Experimental Proce-
dures for detailed description on P. falciparum 20S proteasome
purification). By assessing the inhibition of parasite proteasome
substrate cleavage of Suc-Leu-Leu-Val-Tyr-aminomethylcou-
marin (Suc-LLVY-AMC) upon treatment with these compounds,served
Figure 4. Identification of PR3, an Inhibitor
of Parasite Growth with Low Host Cell
Toxicity through Screening of a Focused
Library of Carfilzomib Analogs
(A) Synchronous ring-stage parasites were treated
for 72 hr with 500 nM of each 670 carfilzomib
analogs. Inhibition of parasite replication was
quantified by flow cytometry and compared to the
Onyx data set for human 20S proteasome inhibi-
tion. The 52 preliminary hits were further tested in
a dilution series in parasite replication assay. Eight
compounds with EC50 < 50 nM were selected for
a 24 hr proteasome inhibition assay with enriched
P. falciparum 20S proteasome. PR3 was identified
as the most potent antiparasitic compound.
(B) Structure of PR3.
(C) Dose response of PR3 on P. falciparum culture
and nonconfluent HFF. Conditions were as
described in Figure 1B. EC50 values are shown as
mean ± SD. Dose response for 60 hr treatment is
shown in Figure S2, and effect of PR3 on
P. falciparum gametocytes is shown in Figure S3.
Error bars are shown as S.E.M.
(D) Proteasome activity in intact trophozoites after
PR3 treatment. Proteasome activity was deter-
mined by monitoring inhibition of the putative b5
subunit using MV151 (2 mM). The IC50 curve was
obtained from three independent experiments
(error bars are shown as SEM); IC50 value is shown
asmean ± SD. A representative probe competition
gel is shown in Figure 5A (lower panel).
See also Figures S2 and S3.
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parasite proteasome and also in replication assays but that had
the weakest activity against the human enzyme. Interestingly,
this compound, given the name PR3, is highly similar in structure
to carfilzomib, differing only by the presence of an additional
methyl group on the P1 sidechain (Figure 4B).
We next assessed the potency of PR3 in P. falciparum tropho-
zoites and compared these results to the activity of the
compound against nonconfluent HFF cells. Although PR3 was
only 100 times less potent than carfilzomib at killing parasites
(EC50 = 2.90 ± 0.15 mM), it showed dramatically reduced toxicity
in the HFF cells (Figure 4C) in 1 hr inhibitor treatment. Even at the
solubility limit of the compound (50 mM), it only reduced viability
of the HFF cells by 20%. Since potency of a covalent inhibitor is
dependent the length of treatment, a short (1 hr) treatment of
trophozoites resulted in an effective concentration that was
higher than that identified in our preliminary screen, where
ring-stage P. falciparum was treated for an extended period
(72 hr). Similar to carfilzomib, the IC50 of the putative b5 protea-
some subunit inhibition in trophozoites after 1 hr treatment
(2.05 ± 0.22 mM) closely matched the EC50 value for parasite
killing in the replication assay (Figure 4D). Thus, PR3 has weak
but effective activity against parasites and reduced toxicity to
host cells.
PR3 Is a Weak Inhibitor of both the Human and Parasite
Proteasome
The fact that PR3 remained effective at killing parasites yet is
a poor inhibitor of the human proteasome suggested that it might
be acting through amechanism of selective parasite proteasomeChemistry & Biology 19, 1535–154inhibition. We initially thought that the addition of the methyl
group on the P1 sidechain could enhance binding in the
P. falciparum 20S proteasome active site or reduce binding to
the human active site. To investigate the selectivity of PR3, we
performed a series of detailed kinetic analysis of both carfilzomib
and PR3 in purified human and parasite 20S proteasomes using
the fluorogenic substrate Suc-LLVY-AMC that reports activity of
the chymotrypsin-like activity of the proteasome (associated
with the b5 subunit) (Table 1; see also Figure S4).
We first determined the observed rate constant (kobs) for
human and P. falciparum 20S proteasome inhibition over a range
of inhibitor concentrations for both carfilzomib and PR3.We then
fit the kobs values to the inhibition model shown in Table 1 that
accounts for reversible binding of the inhibitor (Ki) followed by
covalent modification by the reactive functional group (kinact; Fig-
ure S5). These data suggest that the differences in potency
between these two inhibitors are the result of differences in
binding to the proteasome active site (Ki) rather than differences
in reactivity of the epoxyketone toward the active site threonine
(kinact).
Because epoxyketones are covalent inhibitors, the best
measure of inhibitor potency is the second-order inhibition
constant (ki = kinact/Ki). Ki represents the dissociation constant,
and kinact, the rate of covalent inactivation of the proteasome
by the warhead after inhibitor binding. Calculation of the inhibi-
tion constants (ki) for carfilzomib and PR3 against the human
proteasome confirmed that PR3 is nearly 300 times less potent
than carfilzomib, with a ki of 90,100 and 310 M
1s1 for carfilzo-
mib and PR3, respectively (Table 1). PR3 is also 100-fold less
potent than carfilzomib for the P. falciparum proteasome, with5, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1539
Table 1. Inhibition Constants of Carfilzomib and PR3 in Purified Proteasome
Inhibition Constant
Human 20S Plasmodium 20S
Carfilzomib PR3 Carfilzomib PR3
kinact (s
1) 0.00119 ± 0.00005 0.0012 ± 0.0001 0.00128 ± 0.00005 0.0028 ± 0.0009
Ki (nM) 13.3 ± 1.2 3,900 ± 900 126 ± 6 30,000 ± 11,000
kinact/Ki (M
1s1)a 90,100 ± 5,300 310 ± 50 10,200 ± 100 94 ± 4
See also Figure S4.
aThe second-order inhibition constant ki is equal to kinact/Ki.
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1s1, respec-
tively. Interestingly, PR3 is slightly more potent against the
human b5 proteasome suggesting that the increased thera-
peutic window is not due to selective targeting of the parasite
proteasome.
PR3 Is a Partial Inhibitor of the Host Proteasome
Because our results indicated that PR3 is not a selective inhibitor
of the parasite proteasome, we wanted to determine how this
inhibitor was able to kill parasites but not the host HFF cells.
To compare the effect of a short treatment of PR3 on protea-
some inhibition, we treated intact HFF cells as well as intact
P. falciparum infected red blood cells for 1 hr with the inhibitor
at various concentrations and monitored the levels of residual
activity of the primary proteasome catalytic subunits by labeling
with MV151 (Figure 5A). We found that PR3 has similar potency
against the human and parasite chymotrypsin-like b5 subunit
activity but importantly, it does not inhibit the b2 subunit in the
host proteasome, even at the highest dose tested. Interestingly,
while close to full inhibition of the b5 subunit in the host cell only
has a small effect on viability (Figure 5B), inhibition of this same
activity of the parasite proteasome directly correlates with
a decrease in P. falciparum growth (Figures 5C and 5E). Further-
more, in agreement with recent data suggesting that inhibition of
multiple proteasome activity sites is required to induce cell killing
of mammalian cells (Britton et al., 2009; Mirabella et al., 2011),
we find that a decrease in HFF viability correlates with inhibition
of all three active subunits in the host cell (Figure 5D; see also
Figure S5). Therefore, the window of therapy observed for PR3
is likely due to the fact that PR3 is unable to inhibit all of the
host proteasome subunits.
PR3 Reduces Parasite Growth In Vivo without any Host
Toxicity
Encouraged by the selective parasite killing of PR3 in our culture
model, we proceeded to test PR3 in the in vivo Plasmodium
berghei model. In our studies with the Balb/c female P. berghei
infection model, we consistently observed that parasitemia
develops fairly slowly around the first 5 days of infection, and
thereafter reaches an aggressive and exponential stage of high
parasitemia. Mice were infected with P. berghei and treated
with PR3 through 3 consecutive days of intravenous injections
(Figure 6). We tested a series of doses of PR3 up to 80 mg/kg
(data not shown), and found no noticeable toxic effect in the
mice even at the highest drug dose. To test the effect of PR3
treatment at low parasitemia, we treated mice with 80 mg/kg
dose of PR3 (n = 3) for 3 consecutive days starting 1 day after
infection, when the initial parasitemia is low (0.05%; Figure 6A).1540 Chemistry & Biology 19, 1535–1545, December 21, 2012 ª2012We observed a highly significant decrease in parasitemia
compared to vehicle treated mice (n = 4) on days 2, 3, and 4.
Parasitemia decreased by nearly 90% compared to vehicle
treated mice after 2 days of drug treatment. To investigate if
the effect of PR3 is significant when treatment was administered
at higher parasitemia, where infection reaches an exponential
stage, we treated mice with 80 mg/kg dose of PR3 (n = 5) for 3
consecutive days 5 days after infection when initial parasitemia
is 4.7% (Figure 6B). Again, we found that PR3 has a significant
effect at lowering parasitemia up to 4 days after treatment,
although the effect is less drastic than treatment 1 day after
infection. In both treatment regimes, we were unable to clear
parasites from the host at the end of the drug treatment, sug-
gesting that the in vivo concentration of PR3 is insufficient to
sustain parasite proteasome inhibition and hence only had
a partial effect on parasite growth. Since PR3 is highly similar
in structure to carfilzomib, we postulate that it is also likely to
have a short half-life in vivo and is rapidly degraded after dosing.
DISCUSSION
The proteasome is an essential multi-subunit protease complex
in all eukaryotic cells. Because it is involved in many critical
cellular processes, many have considered it as a therapeutic
target in disease models such as cancer, tuberculosis, and
African sleeping sickness. Lactacystin was the first reported pro-
teasome inhibitor that showed antimalarial effects. Although
lactacystin has potent antiparasitic effects in vitro, it causes
significant host toxicity when administered in a rat P. berghei
model (Gantt et al., 1998). Subsequently, even though many
groups have reported potent effects of a variety of proteasome
inhibitors against asexual, sporozoite (insect-vector) and game-
tocyte stages of P. falciparum, the proteasome has yet to be
validated as a true antimalarial target due to toxicity of these
inhibitors to the host organism.
We report here, to our knowledge, the first studies on the
antimalarial effect of a clinical drug carfilzomib. We found that
carfilzomib is a nano-molar inhibitor of P. falciparum in the
intra-erythrocytic life cycle, and is also effective toward gameto-
cytes (Figure S3). However, in an in vivo P. berghei model, we
found that a modest decrease in host infection is accompanied
by drug-induced toxicity during treatment. We postulate that
this is due to the short half-life of carfilzomib (t1/2 ranges from
5 to 20 min; Yang et al., 2011). In our work, we find that a short
exposure to low concentrations of carfilzomib only results in
growth retardation of the parasite and this is most likely due to
the fact that the parasites are able to rapidly replenish their
proteasomes. Because carfilzomib is rapidly degraded in theElsevier Ltd All rights reserved
Figure 5. PR3 is Nontoxic to Host Cells due
to Partial Inhibition of the Human Protea-
some
(A) MV151 labeling of intact HFF (top) and
P. falciparum trophozoites (bottom) cells treated
with PR3. Quantification of each labeled subunit
(indicated by arrow) is shown below.
(B–E) Comparison of viability (blue line) versus
inhibition of the catalytic proteasome subunit
activities (black lines) after 1 hr incubation of HFF
(B and D) or trophozoites (C, E) with PR3 (B and C)
or carfilzomib (D and E). Proteasome activity was
determined by competition of MV151 labeling from
the gels shown in (A) and Figure S5. The effects
of carfilzomib and PR3 in live trophozoites are
obtained from three independent experiments;
error bars represent SEM for each drug concen-
tration from triplicates.
See also Figure S5.
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to result in parasite clearance without significant compromise
to the health of the host.
In an effort to identify a proteasome inhibitor that has antipar-
asitic effects with low host cell toxicity, we performed a screen of
a focused library of epoxyketone analogs of carfilzomib. In this
screen, we found that most inhibitors that block P. falciparum
replication are also potent human proteasome inhibitors, sug-
gesting there is a strong homology in the active sites of both
the host and parasite proteasome. However, we did identify
one compound, PR3, that is only 100-fold less potent than
carfilzomib in asexual P. falciparum culture, but has virtually
no toxicity in short treatment of HFF cells and produces no
toxic effects when dosed in mice. Like carfilzomib, PR3 also
targets the sexual stage of P. falciparum (gametocytes) at sub-
micromolar concentrations with 24 hr treatment (Figure S3).
Although we initially thought that this was due to selectivity
toward P. falciparum proteasome, our kinetics studies revealed
that ironically, PR3 is a slightly better inhibitor for the chymo-
trypsin-like activity of the host proteasome than the parasite pro-
teasome. Using the proteasome activity-based probe MV151,
we were able to assess inhibition of proteasome activity in intactChemistry & Biology 19, 1535–1545, December 21, 2012host and parasite cells to compare effects
of proteasome inhibition with cell viability.
We found that inhibition of the protea-
some activity even for a short exposure
had a detrimental effect on P. falciparum
viability, and furthermore parasite survival
(EC50) closely correlatedwith the extent of
the putative b5 subunit inhibition as
measured using the active site probe. In
host HFF cells however, nearly full inhibi-
tion of the chymotrypsin-like proteasome
activity for 1 hr had no significant effect on
cell viability. Interestingly, Czesny et al.
also observed a similar effect with epoxo-
micin, a precursor of carfilzomib (Czesny
et al., 2009). In their study, 1 mM of epox-
omicin, a nano-molar inhibitor of humanproteasome only resulted in a 20% decrease in viability in
A549 and NIH 3T3 cells while completely blocking P. falciparum
replication. This, together with the work presented in this study,
shows that partial inhibition of the parasite proteasome can bring
about a significant block to Plasmodium growth.
It is tempting to postulate that just as proliferating cancer cells
are especially sensitive to proteasome inhibition, the parasite’s
highly replicative nature makes it similarly sensitive to protea-
some inhibition. Specifically, proteasome inhibition leads to cell
cycle arrest and activation of apoptotic pathway in cancer cells.
It is likely that proteasome inhibition similarly blocks cell cycle
progression in the parasite, consistent with our findings that
low doses of the compounds slow parasite development (Fig-
ure 3B). Furthermore, our finding that PR3 only inhibits b1 and
b5 subunits of the human proteasome while leaving b2 subunit
fully active, even at the maximum compound solubility, gives us
further insight into design of proteasome inhibitors to target
P. falciparum. As host cells are vulnerable to co-inhibition of all
the subunits as demonstrated by carfilzomib (Figures 5D and
5E), we postulate that proteasome inhibitors that do not block
all host proteasome subunit activities will likely be able to serve
as more selective antiparasitic agents.ª2012 Elsevier Ltd All rights reserved 1541
Figure 6. PR3 Significantly Reduces Para-
site Growth in an In Vivo Model of Malaria
(A) Treatment of mice with PR3 when parasitemia
is low (1 day after infection, initial parasitemia
0.05% for all groups). Mice were inoculated IV
with 1 3 106 of P. berghei parasites and treated
with vehicle (n = 4) or 80 mg/kg PR3 (n = 3) for 3
consecutive days (indicated by bold line) starting
1 day after infection. None of the PR3-treated mice
showed signs of compound toxicity. Parasitemia
was monitored daily from Giemsa-stained thin
blood smears.
(B) Treatment of mice with PR3 when parasite
burden is already high (5 days after infection, initial
parasitemia 4.7%). Mice were inoculated IP with
1 3 106 of P. berghei parasites and treated with
vehicle (n = 5) or 80 mg/kg PR3 (n = 5) via IV
injections for 3 consecutive days (indicated by bold
line) starting on day 5 after infection. Both treat-
ment groups had similar parasitemia (4%–5%)
before treatment was administered. None of the
PR3-treated mice showed signs of compound
toxicity. *p < 0.05. Error bars represent SEM.
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dium growth in a P. berghei mouse model with no host toxicity.
However, at the dose given, we were unable to clear parasitemia
andwe think this is likely due to poor pharmacokinetic properties1542 Chemistry & Biology 19, 1535–1545, December 21, 2012 ª2012 Elsevier Ltd All rights rof the compound. PR3 only differs from
carfilzomib by the presence of a single
methyl group suggesting that both inhibi-
tors are likely to have similar PK proper-
ties. As such, even at a high dose of
80 mg/kg, the inhibitor is likely to be
rapidly degraded and the resulting
concentration of PR3 in blood is insuffi-
cient to lead to complete parasite
clearance.
SIGNIFICANCE
This study provides evidence that the
Plasmodium falciparum proteasome
can be safely targeted by small mole-
cule inhibitors. It is possible to selec-
tively kill Plasmodium using our lead
compound PR3 due to the inability of
PR3 to fully inhibit all of the host pro-
teasome subunits. Furthermore, partial
inhibition of the proteasome is suffi-
cient to significantly block Plasmo-
dium growth and this suggests
that inhibitors with selectivity for the
Plasmodium proteasome over the
human proteasome are likely to have
an even greater therapeutic window
in vivo. Furthermore, as sustained
inhibition of the parasite proteasome
will lead to parasite death, compounds
with better stability in vivo will benecessary for any antimalarial agents based on proteasome
inhibitors to be effective. As such, the P. falciparum protea-
some represents a promising therapeutic target that can
complement other existing antimalarial drugs in noveleserved
Chemistry & Biology
The Proteasome as a Drug Target in Plasmodiumcombination therapies. Studies that focus on compounds
with enhanced selectivity for the P. falciparum proteasome
are ongoing.
EXPERIMENTAL PROCEDURES
Parasite Culture, Harvesting of Life Cycle Stages, and Lysate
Preparation
Clones 3D7 and D10 of P. falciparumwere cultured and synchronized inmedia
containing the serum substitute Albumax (Invitrogen) using standard proce-
dures (Trager and Jensen, 1976). Synchronous parasite cultures for life stage
lysates and replication assays were obtained using treatments with 5%
sorbitol to maintain parasites that have an 6 hr window of synchrony.
To release parasites from infected red blood cells, infected red cells were
selectively lysed with 0.15% saponin (Calbiochem) and the parasite pellet
was prepared in 1X PBS. Pelleted parasites were stored at 80C for further
analyses. Lysates from asynchronous and synchronous parasite pellets
were prepared by the addition of an equal volume of hypotonic lysis buffer
(50 mM Tris pH 7.4, 5 mM MgCl2, 1 mM DTT) to the parasite pellet on ice for
1 hr with occasional vortexing. Lysates were spun at 6000 3 g for 10 min
and the resulting supernatant was quantified by Bradford assay (Pierce) and
used for activity assays.
Tightly synchronized parasites for stage specificity experiments were
obtained by enriching for mature schizonts on a 70% percoll gradient as previ-
ously described (Blackman, 1994). Enriched schizonts were subsequently
allowed to infect fresh red blood cells, and schizonts that did not rupture in
the first hour were lysed by sorbitol treatment to create an 1 hr window of
synchrony.
P. falciparum Replication Assay and Proteasome Inhibitor Screen
To evaluate carfilzomib and to screen the Onyx (formerly Proteolix) compound
library, synchronous ring-stage parasites (9 hr post invasion; 1% parasitemia;
0.5% hematocrit) were treated with the library of inhibitors at a final concentra-
tion of 500 nM for 72 hr at 37C in a 96-well-plate format, fixed with 0.05%
glutaraldehyde (Sigma) in 1X PBS overnight at 4C, permeabilized with
0.25% Triton X-100 in 1X PBS for 5 min at room temperature (25C), resus-
pended in 200 uL 1X PBS, and stained with a 1:100 dilution of a 5 mg/ml
working solution of propidium iodide (Sigma) in deionized water. Parasite
replication was monitored by observation of a propidium iodide positive pop-
ulation (infected) and propidium iodide negative population (uninfected) using
a BD FACScan flow cytometer (Becton, Dickinson and Co.) located in the
Stanford Shared FACS Facility at Stanford University. The infected and
uninfected red blood cell populations were quantified using Flowjo 9.1.11.
Parasitemia was calculated as the number of infected cells divided by
the number of total cells and was normalized to the average of the DMSO
treated controls (average of 3–6 DMSO controls per compound plate).
Screening was performed in duplicate. Any compound giving a value below
0.5 relative parasitemia was considered a preliminary hit. Parasite replication
data was compared to the existing Onyx human data set using software avail-
able on the Collaborative Drug Discovery database website (http://www.
collaborativedrug.com/).
Subsequent replication assays were performed as described above, but
with synchronous population of early-mid trophozoites with various inhibitor
concentrations by treating cultures for 1 hr followed by washout of inhibitor
to better mimic in vivo treatment or 60 hr continuous treatment. For the
washout assays, cultures were treated with inhibitor for 1 hr at 37C, washed
three timeswith freshmedia, and incubatedwith freshmedia for a further 59 hr.
Data were obtained and analyzed using GraphPad Prism 5.0d.
Enrichment of the P. falciparum Proteasome from Schizont Lysate
The P. falciparum proteasome was enriched through a two-step column
purification. A synchronous population of late schizonts (40–48 hr) was
harvested from culture and lysates were obtained as described above. Lysates
were then pooled and concentrated on a 100 kD spin column (Amicon Ultra
100k Ultracel) for 20 min at 4C yielding 500 ml containing 20 mg/ml total
parasite protein. The entire sample was loaded onto a 5 ml anion exchange
HiTrap DEAE-FF column (GE Healthcare) and eluted with a gradient bufferChemistry & Biology 19, 1535–154from 20 mM Tris pH 7.4 to 1M NaCl in 20 mM Tris pH7.4. 1.5 ml fractions
were collected, and fractions were analyzed for presence of proteasome using
fluorogenic assay with 20 mM Succinyl-Leu-Leu-Val-Tyr-aminocoumarin
(Suc-LLVY-amc, Boston Biochem)). Fractions with Suc-LLVY-amc activity
were pooled and concentrated on a 100kD spin column into gel filtration
buffer (25 mM Tris pH 7.4, 100 mM NaCl, 10% glycerol). This is then loaded
onto a Superose-6 gel filtration column (GE Healthcare) and 500 ml fractions
were collected. Fractions were analyzed for the presence of proteasome by
fluorgenic substrate assay (as above) and the proteasome activity-based
probe MV151 (Verdoes et al., 2006). Active fractions were combined and
concentrated on a 100-kD spin column. The final proteasome-enriched
preparation was evaluated for purity by silver stain (Figure S1E; Invitrogen
SilverQuest).
Proteasome Substrate Activity Assays
Proteasome chymotrypsin-like activity was determined using succinyl-Leu-
Leu-Val-Tyr-AMC (LLVY-AMC; 20 mM) with purified human 20S proteasome
(2 nM) as previously described (Demo et al., 2007) or enriched parasite pro-
teasome. For the human 20S proteasome, inhibition was assessed by adding
inhibitor and substrate simultaneously to the enzyme in proteasome assay
buffer (50 mM HEPES pH 8.0, 0.5 mM EDTA, 0.03% SDS) and measuring
AMC fluorophore release at 340/465 nm at 27C with a plate-based specto-
photometer (Spectramax M5). Slopes of AMC product formation between
60 and 75 min were determined and normalized relative to DMSO. The
50% inhibitory concentration (IC50) for each inhibitor was determined by
non-linear regression using GraphPad Prism software. For the enriched
P. falciparum proteasome, inhibition was assessed by adding inhibitor
and substrate simultaneously to the enzyme in assay buffer (50 mM Tris
pH 7.4, 5 mM MgCl2, 1 mM DTT), and measuring AMC fluorophore release
at 340/465 nm at 27C.
To calculate inhibition constants in human and P. falciparum proteasome,
the LLVY-AMC cleavage assay described above was repeated at 200 mM
LLVY-AMC and a range of inhibitor concentrations (0–5 nM for carfilzomib
and 0–10 mM for PR-3). Slopes for each inhibitor concentrationwere calculated
at 30 min intervals over 3 hr and normalized to DMSO to generate inactivation
curves. First-order rate constants (kobs) were derived from inactivation curves,
and inhibition constants (kI) were calculated from the relationship of kobs with
each inhibitor concentration using KaleidaGraph software.
Proteasome Labeling with MV151
The synthesis of MV151 is described in Verdoes et al. (2006). For all lysates
or purified proteasome labeling experiments, MV151 is used at a final con-
centration of 2 mM followed by incubation at 37C for 1 hr. The samples are
then denatured by adding loading dye and boiling, and ran on a 12% SDS
PAGE. Gels are then scanned at the TAMRA channel on a Typhoon Scanner
(GE Healthcare). Quantification of the intensity of the labeled proteins is
done using Image J.
Assessment of P. falciparum Proteasome Activity in Intact Inhibitor-
Treated Parasites
P. falciparum is cultured at around 15% parasitemia to ensure sufficient para-
site is available for proteasome labeling. P. falciparum culture is first treated for
the indicated amount of time, and spun down at 3200 rpm to remove inhibitor.
Culture is then washed three times in fresh media, and parasite pellets are
obtained as described above. P. falciparum proteasome is labeled by incu-
bating at least 2 mg of parasite lysate obtained from the pellet (see above)
with 2 mM of MV151. To assess proteasome inhibition, the intensity of the
proteasome labeling is quantified by Image J and the amount of proteasome
inhibition is taken as a percentage of the DMSO treated parasite lysate. IC50
curves are obtained by fitting the data using GraphPad Prism 5.0d.
Infection with P. berghei and Inhibitor Treatment of Mice
All mouse experiments were approved by the Stanford Administration Panel
on Laboratory Animal Care and strictly followed their specific guidelines. For
each drug assay, Balb/c mice (20 g) were infected by intravenous (IV) or
intraperitoneal (IP) injection with 1 3 106 P. berghei parasites isolated
from an infected mouse on Day 0. Carfilzomib (0.5 and 1 mg/kg), PR-3
(80 mg/kg), or vehicle (10 mM citrate buffer, 20% kleptose) was administered5, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1543
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three to five mice were used. Due to technical challenge of 3 consecutive
days of tail vein injections, some doses were administered as retro-orbital
injection when required. Treatment with 80 mg/kg PR3 (Figure 6B) for all
mice is administered as tail vein injection (day 5) and retro-orbital injections
(day 6 and 7). During drug treatment, health of mice is assessed by observing
physical appearances and activities of mice. Weight of mice is also moni-
tored daily after infection. Parasitemia was monitored daily by thin blood
smear and quantified by light microscope counting or flow cytometry as
described above for P. falciparum. For quantification (for < 20% parasitemia)
with thin blood smears, a minimum of five fields each containing at least 400
red blood cells were counted for parasite infection. A Student’s one-tailed
t test was performed to assess statistical relevance of difference in treatment
groups.
P. falciparum Gametocyte Viability Assay
P. falciparum (3D7) parasites were induced to produce gametocytes by
standard method (Ifediba and Vanderberg, 1981). Inhibitor efficacy was tested
ten days after setting up the gametocyte culture, when it contained stage III
and IV gametocytes. One milliliter of the culture was transferred to each well
of a 24-well plate and treated with inhibitor or DMSO as a control for 24 hr at
37C. Coded Giemsa-stained parasite smears from each well were counted
and gametocyte stage determined by morphology by an experienced techni-
cian. Small, amorphous, densely-stained inclusions in the red blood cells were
not counted as live parasites.
HFF Cell Toxicity Assays and Human Proteasome Labeling
See Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.chembiol.2012.09.019.
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